Hyperostosis corticalis generalisata

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3416OMIM:239100M85.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hyperostosis corticalis generalisata, also known as Van Buchem disease, is a rare inherited skeletal disorder characterized by progressive thickening (hyperostosis) of the cortical bone throughout the body. The condition primarily affects the skull, mandible (jawbone), clavicles, ribs, and long bones. The excessive bone growth leads to a characteristic set of clinical features including enlargement and widening of the jaw, facial distortion, and cranial nerve compression. Compression of cranial nerves within narrowed bony foramina can result in facial nerve palsy (Bell's palsy), hearing loss, and visual impairment. Increased intracranial pressure may also occur due to thickening of the skull vault. The condition typically becomes apparent during childhood or puberty and progresses throughout life. The disease is caused by a deletion in the regulatory region downstream of the SOST gene on chromosome 17q21, which leads to reduced production of sclerostin, a protein that normally inhibits bone formation. Without adequate sclerostin, osteoblastic activity is excessive, resulting in continuous bone deposition. Van Buchem disease is inherited in an autosomal recessive manner and is particularly prevalent in a Dutch population from a village in the province of Groningen in the Netherlands, where a founder effect has been identified. There is currently no cure for hyperostosis corticalis generalisata. Treatment is primarily symptomatic and supportive. Surgical decompression of cranial nerves may be necessary to address facial palsy, hearing loss, or optic nerve compression. Regular monitoring by a multidisciplinary team including orthopedic specialists, neurologists, ophthalmologists, and audiologists is recommended. Interestingly, research into the SOST gene and sclerostin pathway has contributed significantly to the development of anti-sclerostin antibody therapies (such as romosozumab) for osteoporosis, though these therapies are not used to treat Van Buchem disease itself.

Also known as:

Clinical phenotype terms— hover any for plain English:

Cranial hyperostosisHP:0004437Diaphyseal undertubulationHP:0005019Generalized osteosclerosisHP:0005789
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Hyperostosis corticalis generalisata.

View clinical trials →

No actively recruiting trials found for Hyperostosis corticalis generalisata at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hyperostosis corticalis generalisata community →

No specialists are currently listed for Hyperostosis corticalis generalisata.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hyperostosis corticalis generalisata.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hyperostosis corticalis generalisataForum →

No community posts yet. Be the first to share your experience with Hyperostosis corticalis generalisata.

Start the conversation →

Latest news about Hyperostosis corticalis generalisata

No recent news articles for Hyperostosis corticalis generalisata.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hyperostosis corticalis generalisata

What is Hyperostosis corticalis generalisata?

Hyperostosis corticalis generalisata, also known as Van Buchem disease, is a rare inherited skeletal disorder characterized by progressive thickening (hyperostosis) of the cortical bone throughout the body. The condition primarily affects the skull, mandible (jawbone), clavicles, ribs, and long bones. The excessive bone growth leads to a characteristic set of clinical features including enlargement and widening of the jaw, facial distortion, and cranial nerve compression. Compression of cranial nerves within narrowed bony foramina can result in facial nerve palsy (Bell's palsy), hearing loss,

How is Hyperostosis corticalis generalisata inherited?

Hyperostosis corticalis generalisata follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hyperostosis corticalis generalisata typically begin?

Typical onset of Hyperostosis corticalis generalisata is childhood. Age of onset can vary across affected individuals.